Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus

by Zacks Equity Research

IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.

Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Alexion Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.

Alexion Pharmaceuticals (ALXN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alexion (ALXN) delivered earnings and revenue surprises of 11.86% and 2.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings?

by Zacks Equity Research

Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q2 results.

Is a Beat in Store for Repligen (RGEN) This Earnings Season?

by Zacks Equity Research

On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.

AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.

Nalak Das headshot

Buy 5 High-Flying Stocks Ahead of Q2 Earnings This Week

by Nalak Das

It will be prudent to invest in stocks that are likely to beat earnings estimates in the second quarter this week.

What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?

by Zacks Equity Research

On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.

Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Alexion (ALXN) possesses solid growth attributes, which could help it handily outperform the market.

Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXN or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALXN vs. ALKS: Which Stock Is the Better Value Option?

Alexion (ALXN) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Buy for Solid Returns

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 17th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Alexion's Ultomiris Receives EU Approval for PNH in Adults

by Zacks Equity Research

Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

Alexion Receives FDA Approval for Label Expansion of Soliris

by Zacks Equity Research

Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Alexion's sBLA for Ultomiris Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

Ekta Bagri headshot

3 Big Biotechs Hold Growth Potential in Second Half of 2019

by Ekta Bagri

We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH

by Zacks Equity Research

Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.